Acetylcholine receptor antibody–mediated animal models of myasthenia gravis and the role of complement
Authors:
- 21 January 2018
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1413 (1) , 136-142
Abstract
Because of the failure of many promising therapeutics identified in preclinical evaluation, funding sources have established guidelines for increased rigor in animal evaluations. The myasthenia gravis (MG) community of scientists has developed guidelines for preclinical assessment for potential MG treatments. Here, we provide a focused summary of these recommendations and the role of complement in disease development in experimental models of MG.Keywords
Funding Information
- Muscular Dystrophy Association (17990 (L.L.K.), 508240 (H.J.K.))
This publication has 42 references indexed in Scilit:
- Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal ExperimentsPLOS Medicine, 2013
- A call for transparent reporting to optimize the predictive value of preclinical researchNature, 2012
- Enhancing translation: Guidelines for standard pre-clinical experiments in mdx miceNeuromuscular Disorders, 2012
- Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravisMuscle & Nerve, 2011
- Paths reunited: Initiation of the classical and lectin pathways of complement activationImmunobiology, 2010
- Novel complement inhibitor limits severity of experimentally myasthenia gravisAnnals of Neurology, 2009
- Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivoMolecular Immunology, 2008
- Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClinical and Experimental Immunology, 2006
- Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravisExperimental Neurology, 2004
- Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravisJournal of Neuroimmunology, 1996